

Cetuximab for the treatment of advanced non-small cell lung cancer

<http://guidance.nice.org.uk/TA/Wave15/4>

Dear Consultees and commentators,

Following the opinion issued after the July meeting of the Committee for Medicinal Products for Human (CHMP) of the European Medicines Agency (EMA) this appraisal remains suspended. We will inform consultees of the next steps when we have more information.

If you have any questions, please contact me.

Kind regards,

Jeremy

Jeremy Powell

Technology Appraisal Project Manager

National Institute for Health and Clinical Excellence

MidCity Place | 71 High Holborn | London WC1V 6NA | United Kingdom

Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830